Bimekizumab cumulative clinical benefit in patients with moderate to severe hidradenitis suppurativa through 1 year of the BE HEARD I&II phase 3 trials. SKIN The Journal of Cutaneous Medicine, [S. l.], v. 8, n. 6, p. s477, 2024. DOI: 10.25251/skin.8.supp.477. Disponível em: https://skin.dermsquared.com/skin/article/view/3079. Acesso em: 19 may. 2025.